Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Figure 2

Kaplan-Meier analysis of metastasis-free survival in the training (84 patients) and the validation set (78 patients) of lymph node-positive patients with estrogen receptor-positive tumors treated with adjuvant anthracycline containing therapy and stratified by the DNA methylation status of CDO1. Median methylation of the respective population was used as the cut point

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us